Product details
Catalog number BNC042481-100
Price for BNC042481-100
Size / count 1x 100 µL
Stratifin is a p53-induced tumor suppressor gene which is activated in response to DNA damage, causing cell cycle arrest at G2 phase by blocking cdc2-cyclin B1 complex from entering the nucleus. It is inactivated in breast, lung, prostate, liver and gastric cancer. It is associated with poor prognosis when its down-regulation is observed in epithelial ovarian cancer. SFN expression could contribute to cancer cell proliferation and the development and/or progression of human gastrointestinal cancer. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
The catalog number for 14-3-3 Sigma / Stratifin (CPTC-SFN-2), CF405S conjugate, 0.1mg/mL is BNC042481-100.
14-3-3 Sigma / Stratifin (CPTC-SFN-2), CF405S conjugate, 0.1mg/mL is available in the following size(s): 1x 100 µL.
14-3-3 Sigma / Stratifin (CPTC-SFN-2), CF405S conjugate, 0.1mg/mL is currently made to order / not held in immediate stock. Contact us for lead time.
14-3-3 Sigma / Stratifin (CPTC-SFN-2), CF405S conjugate, 0.1mg/mL is manufactured by Biotium.
Estimated delivery time for 14-3-3 Sigma / Stratifin (CPTC-SFN-2), CF405S conjugate, 0.1mg/mL is approximately 15 business day(s), depending on your location.
The safety data sheet for 14-3-3 Sigma / Stratifin (CPTC-SFN-2), CF405S conjugate, 0.1mg/mL is available here: https://biotium.com/wp-content/uploads/2018/06/SDS-primary-antibodies.pdf.
Stratifin is a p53-induced tumor suppressor gene which is activated in response to DNA damage, causing cell cycle arrest at G2 phase by blocking cdc2-cyclin B1 complex from entering the nucleus. It is inactivated in breast, lung, prostate, liver and gastric cancer. It is associated with poor prognos
Lead times depend on the product type: custom polyclonal antibodies typically take 12-14 weeks, monoclonal antibodies 15-17 weeks, made-to-order recombinant proteins 4-8 weeks, and made-to-order recombinant antibodies 6-8 weeks. These are estimates and may shift due to production delays.
A recommended dilution range for each validated application is provided on the datasheet, but optimal dilution should be titrated for your specific experimental system, sample type, and detection method.
Post-reconstitution storage guidance is listed on the datasheet, typically requiring aliquoting and storage at -20°C or -80°C to preserve activity.